Published in AIDS Weekly, October 23rd, 2006
Based on the results of Viral Genetics' recent clinical trial, Rosenberg was appointed to a more active leadership role in the development of VGV-1 and thymus nuclear protein. He will be advising the company on future studies and the design of a clinical development strategy toward the commercialization of VGV-1 in the U.S.
Rosenberg succeeds Ronald Moss as the chairman of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.